HealthEquity, Inc. $HQY Shares Sold by GW&K Investment Management LLC

GW&K Investment Management LLC lowered its position in HealthEquity, Inc. (NASDAQ:HQY) by 10.4% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 446,993 shares of the company’s stock after selling 51,905 shares during the quarter. GW&K Investment Management LLC’s holdings in HealthEquity were worth $42,362,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently added to or reduced their stakes in the company. Vanguard Group Inc. raised its holdings in shares of HealthEquity by 2.9% in the 3rd quarter. Vanguard Group Inc. now owns 8,746,255 shares of the company’s stock worth $828,883,000 after purchasing an additional 243,549 shares during the period. Westfield Capital Management Co. LP increased its position in HealthEquity by 35.7% during the 3rd quarter. Westfield Capital Management Co. LP now owns 1,716,658 shares of the company’s stock worth $162,688,000 after purchasing an additional 451,450 shares in the last quarter. Dimensional Fund Advisors LP raised its holdings in HealthEquity by 2.5% in the third quarter. Dimensional Fund Advisors LP now owns 1,559,008 shares of the company’s stock valued at $147,751,000 after buying an additional 38,154 shares during the period. JPMorgan Chase & Co. raised its holdings in HealthEquity by 11.5% in the third quarter. JPMorgan Chase & Co. now owns 1,205,077 shares of the company’s stock valued at $114,205,000 after buying an additional 124,283 shares during the period. Finally, Charles Schwab Investment Management Inc. lifted its position in HealthEquity by 2.6% during the second quarter. Charles Schwab Investment Management Inc. now owns 1,129,115 shares of the company’s stock valued at $118,286,000 after buying an additional 28,145 shares in the last quarter. Hedge funds and other institutional investors own 99.55% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on HQY. Jefferies Financial Group set a $108.00 price objective on shares of HealthEquity in a research report on Thursday, February 19th. Citigroup reiterated an “outperform” rating on shares of HealthEquity in a report on Thursday, December 4th. JPMorgan Chase & Co. boosted their price objective on HealthEquity from $126.00 to $129.00 and gave the stock an “overweight” rating in a research note on Thursday, December 4th. Citizens Jmp set a $122.00 target price on HealthEquity in a research report on Thursday, December 4th. Finally, UBS Group set a $110.00 target price on HealthEquity in a report on Tuesday, February 17th. One investment analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, HealthEquity has an average rating of “Moderate Buy” and an average price target of $112.00.

HealthEquity Trading Up 0.9%

Shares of HQY opened at $81.15 on Thursday. HealthEquity, Inc. has a one year low of $72.76 and a one year high of $116.65. The stock has a 50-day moving average price of $83.82 and a 200 day moving average price of $90.92. The company has a debt-to-equity ratio of 0.46, a quick ratio of 4.13 and a current ratio of 4.13. The company has a market capitalization of $6.93 billion, a P/E ratio of 37.22, a P/E/G ratio of 1.00 and a beta of 0.26.

HealthEquity (NASDAQ:HQY) last posted its quarterly earnings data on Wednesday, December 3rd. The company reported $1.01 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.90 by $0.11. The company had revenue of $322.16 million for the quarter, compared to the consensus estimate of $320.92 million. HealthEquity had a return on equity of 12.94% and a net margin of 14.86%.HealthEquity’s revenue for the quarter was up 7.2% compared to the same quarter last year. During the same period in the previous year, the business earned $0.78 EPS. Sell-side analysts forecast that HealthEquity, Inc. will post 2.32 EPS for the current fiscal year.

Insider Buying and Selling

In other HealthEquity news, EVP Delano Ladd sold 1,500 shares of the stock in a transaction on Friday, December 19th. The shares were sold at an average price of $94.72, for a total transaction of $142,080.00. Following the transaction, the executive vice president directly owned 73,979 shares in the company, valued at $7,007,290.88. This represents a 1.99% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Elimelech Rosner sold 10,959 shares of the firm’s stock in a transaction on Thursday, December 18th. The stock was sold at an average price of $95.45, for a total transaction of $1,046,036.55. Following the transaction, the executive vice president directly owned 45,742 shares of the company’s stock, valued at approximately $4,366,073.90. This represents a 19.33% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 1.50% of the stock is currently owned by company insiders.

HealthEquity Company Profile

HealthEquity, Inc (NASDAQ: HQY) is a leading administrator of consumer-directed health accounts and related benefit solutions in the United States. Founded in 2002 and headquartered in Draper, Utah, the company specializes in health savings accounts (HSAs) and offers complementary services such as flexible spending accounts (FSAs), health reimbursement arrangements (HRAs), COBRA administration and commuter benefits. Through its technology-driven platform, HealthEquity enables employers, health plans and individuals to streamline account management, improve cost transparency and encourage more informed healthcare spending.

Serving millions of members across all 50 states, HealthEquity leverages an open-architecture ecosystem that integrates with health plans, payroll providers and financial institutions.